MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-23-2026
West Pharmaceutical Services Accounts Receivables 2011-2026 | WST
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables West Pharmaceutical Services
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 574 M | 552 M | 512 M | 507 M | 489 M | 385 M | 319 M | 288 M | 253 M | 200 M | 181 M | 179 M | 186 M | 175 M | 147 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 574 M | 147 M | 330 M |
Quarterly Accounts Receivables West Pharmaceutical Services
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 686 M | 574 M | 625 M | 582 M | 544 M | 552 M | 524 M | 479 M | 524 M | 512 M | 519 M | 534 M | 513 M | 507 M | 485 M | - | 499 M | 489 M | 476 M | 480 M | 466 M | 385 M | 385 M | 385 M | 385 M | 319 M | 319 M | 319 M | 319 M | 288 M | 288 M | 288 M | 288 M | 253 M | 253 M | 253 M | 253 M | 200 M | 200 M | 200 M | 200 M | 181 M | 181 M | 181 M | 181 M | 179 M | 179 M | 179 M | 179 M | 186 M | 186 M | 186 M | 186 M | 175 M | 175 M | 175 M | 175 M | 147 M | 147 M | 147 M | 147 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 686 M | 147 M | 331 M |
Accounts Receivables of other stocks in the Medical instruments industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
23 K | - | - | $ 810 M |  USA |
 |
Ekso Bionics Holdings
EKSO
|
7.31 M | $ 11.19 | 1.85 % | $ 27.1 M | USA |
 |
The Cooper Companies
COO
|
829 M | $ 64.76 | 0.52 % | $ 12.9 B | USA |
 |
iRhythm Technologies
IRTC
|
75.7 M | $ 125.16 | 2.3 % | $ 4.01 B | USA |
 |
Repro Med Systems
KRMD
|
6.21 M | $ 3.94 | -0.51 % | $ 182 M | USA |
 |
Milestone Scientific
MLSS
|
313 K | $ 0.31 | -2.41 % | $ 25.4 M | USA |
 |
Haemonetics Corporation
HAE
|
203 M | $ 59.95 | -0.05 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
1.03 M | $ 6.1 | -1.21 % | $ 51.7 K | USA |
 |
ICU Medical
ICUI
|
181 M | $ 121.97 | -2.29 % | $ 3.01 B | USA |
 |
Microbot Medical
MBOT
|
159 K | $ 2.21 | 0.45 % | $ 101 M |  Israel |
 |
Envista Holdings Corporation
NVST
|
430 M | $ 27.04 | 0.93 % | $ 4.54 B | USA |
 |
Isoray
ISR
|
6 K | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
1.53 B | $ 482.7 | 0.1 % | $ 172 B | USA |
 |
Glaukos Corporation
GKOS
|
39.8 M | $ 123.75 | 1.72 % | $ 5.99 B | USA |
 |
STERIS plc
STE
|
1.04 B | $ 221.43 | -0.17 % | $ 21.8 B | USA |
 |
Masimo Corporation
MASI
|
141 M | $ 178.55 | -0.04 % | $ 9.52 B | USA |
 |
InfuSystem Holdings
INFU
|
16.9 M | $ 10.83 | 4.94 % | $ 224 M | USA |
 |
Teleflex Incorporated
TFX
|
346 M | $ 137.51 | 0.7 % | $ 6.14 B | USA |
 |
Merit Medical Systems
MMSI
|
204 M | $ 68.43 | -0.22 % | $ 4.05 B | USA |
 |
Utah Medical Products
UTMD
|
3.52 M | $ 68.25 | 1.61 % | $ 221 M | USA |
 |
Pulse Biosciences
PLSE
|
274 K | $ 23.51 | 2.11 % | $ 1.58 B | USA |
 |
Retractable Technologies
RVP
|
7.9 M | $ 0.65 | 1.41 % | $ 19.5 M | USA |
 |
Pro-Dex
PDEX
|
16.4 M | $ 52.07 | -0.06 % | $ 171 M | USA |
 |
LeMaitre Vascular
LMAT
|
33.6 M | $ 114.44 | 0.87 % | $ 2.59 B | USA |
 |
Predictive Oncology
POAI
|
32.1 K | - | - | $ 31.1 M | USA |
 |
STAAR Surgical Company
STAA
|
50.1 M | $ 26.27 | 2.34 % | $ 1.3 B | USA |
 |
BioLife Solutions
BLFS
|
9.17 M | $ 21.82 | 2.06 % | $ 1.01 B | USA |
 |
Stereotaxis
STXS
|
5.85 M | $ 1.92 | -0.78 % | $ 175 M | USA |
 |
Baxter International
BAX
|
1.7 B | $ 18.38 | 1.24 % | $ 9.43 B | USA |
 |
ResMed
RMD
|
576 M | $ 221.41 | 0.77 % | $ 32.3 B | USA |
 |
AtriCure
ATRC
|
66.7 M | $ 28.94 | -1.16 % | $ 1.38 B | USA |
 |
Harvard Bioscience
HBIO
|
16 M | $ 6.88 | 0.29 % | $ 305 M | USA |
 |
NeuroMetrix
NURO
|
193 K | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
42.9 M | $ 11.26 | 1.4 % | $ 460 M | USA |
 |
Becton, Dickinson and Company
BDX
|
2.99 B | $ 153.02 | 0.59 % | $ 44 B | USA |
 |
Nephros
NEPH
|
1.5 M | $ 2.89 | 0.7 % | $ 30 M | USA |
 |
OraSure Technologies
OSUR
|
22.2 M | $ 3.01 | 0.33 % | $ 221 M | USA |
 |
Repligen Corporation
RGEN
|
124 M | $ 118.66 | 0.9 % | $ 6.61 M | USA |